Fortress Biotech, Inc.
FBIO
$1.64
-$0.02-1.21%
NASDAQ
| 12/31/2024 | 09/30/2024 | 06/30/2024 | 03/31/2024 | 12/31/2023 | |
|---|---|---|---|---|---|
| Revenue | 56.68M | 62.50M | 63.36M | 65.64M | 64.99M |
| Total Other Revenue | 1.00M | 19.00M | 19.26M | 19.47M | 19.52M |
| Total Revenue | 57.68M | 81.50M | 82.62M | 85.11M | 84.51M |
| Cost of Revenue | 77.78M | 81.92M | 93.97M | 114.67M | 128.97M |
| Gross Profit | -20.10M | -421.00K | -11.34M | -29.55M | -44.45M |
| SG&A Expenses | 83.93M | 77.08M | 76.82M | 80.44M | 87.84M |
| Depreciation & Amortization | 3.42M | 3.77M | 3.77M | 3.77M | 3.77M |
| Other Operating Expenses | -4.55M | -- | -- | -- | -- |
| Total Operating Expenses | 160.58M | 162.77M | 174.56M | 198.87M | 220.57M |
| Operating Income | -102.90M | -81.27M | -91.93M | -113.76M | -136.06M |
| Income Before Tax | -120.45M | -123.08M | -107.04M | -137.51M | -153.63M |
| Income Tax Expenses | 405.00K | 448.00K | 520.00K | 520.00K | 520.00K |
| Earnings from Continuing Operations | -120.86 | -123.53 | -107.56 | -138.03 | -154.15 |
| Earnings from Discontinued Operations | -- | -- | -- | -- | -- |
| Extraordinary Item & Accounting Change | -- | -- | -- | -- | -- |
| Minority Interest in Earnings | 74.86M | 75.01M | 66.87M | 83.52M | 93.52M |
| Net Income | -46.00M | -48.51M | -40.69M | -54.52M | -60.64M |
| EBIT | -102.90M | -81.27M | -91.93M | -113.76M | -136.06M |
| EBITDA | -98.44M | -76.74M | -87.17M | -108.48M | -130.06M |
| EPS Basic | -2.90 | -3.58 | -3.75 | -6.67 | -9.11 |
| Normalized Basic EPS | 0.15 | 1.27 | -0.38 | -0.25 | -0.33 |
| EPS Diluted | -2.90 | -3.58 | -3.75 | -6.67 | -9.11 |
| Normalized Diluted EPS | 0.15 | 1.27 | -0.38 | -0.25 | -0.33 |
| Average Basic Shares Outstanding | 81.18M | 65.92M | 53.72M | 42.78M | 32.42M |
| Average Diluted Shares Outstanding | 81.18M | 65.92M | 53.72M | 42.78M | 32.42M |
| Dividend Per Share | -- | -- | -- | -- | -- |
| Payout Ratio | -8.73% | -12.42% | -19.74% | -14.73% | -13.25% |